活動性乾癬性関節炎に対するrisankizumab の有効性と安全性: KEEPsAKE 1 試験の52週結果
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac607
Risankizumab (RZB) improves the signs and symptoms of PsA, with efficacy maintained through 52 weeks. Alongside the efficacy data, this analysis of KEEPsAKE 1 also evaluates the safety and tolerability profile of RZB.